Skip to content

Famciclovir

FDA-approved product (tablet, oral), marketed as Famciclovir, Famvir.

Registered studies
25
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famciclovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye infection
  • Genital herpes
  • Herpes Labialis
  • Herpes Zoster
  • Immunodeficiency disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors; Antivirals
FDA pharmacologic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB09; WHO ATC S01AD07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famciclovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain

    NCT07344246 · start 2026-09-01

    Registered record
    Registry ID
    NCT07344246
    Conditions
    Herpes Zoster Pain
    Interventions
    intravenous infusion with 4 mg dexamethasone palmitate or 8 mg dexamethasone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-12-01
    Enrolment
    954

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster Pain
    Interventionintravenous infusion with 4 mg dexamethasone palmitate or 8 mg dexamethasone palmitate
    PhaseNot applicable
    Registry statusNot yet recruiting
  • Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

    NCT07099157 · start 2025-08-25

    Registered record
    Registry ID
    NCT07099157
    Conditions
    Herpes Zoster
    Interventions
    Brivudine; Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08-25
    Completion
    2027-12-31
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster
    InterventionBrivudine; Famciclovir
    PhasePhase 4
    Registry statusRecruiting
  • Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain

    NCT06798662 · start 2025-02-01

    Registered record
    Registry ID
    NCT06798662
    Conditions
    Herpes Zoster (HZ)
    Interventions
    Ultrasound-Guided Pulsed Radiofrequency (PRF); Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine); Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine); Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine); Drug (famciclovir and gabapentin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2025-06-10
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster (HZ)
    InterventionUltrasound-Guided Pulsed Radiofrequency (PRF); Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine); Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine); Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine) +1 more
    PhaseNot applicable
    Registry statusNot yet recruiting
  • Effect of Mechanical Ventilation on Radiofrequency Ablation in Atrial Fibrillation

    NCT06791915 · start 2025-01-01

    Registered record
    Registry ID
    NCT06791915
    Conditions
    Radiofrequency Ablation; Atrial Fibrillation; Mechanical Ventilation
    Interventions
    Radiofrequency Ablation with FCV.; Radiofrequency Ablation with VCV.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-01
    Completion
    2025-08-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadiofrequency Ablation; Atrial Fibrillation; Mechanical Ventilation
    InterventionRadiofrequency Ablation with FCV.; Radiofrequency Ablation with VCV.
    PhaseNot recorded
    Registry statusRecruiting
  • Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

    NCT05894954 · start 2023-07-31

    Registered record
    Registry ID
    NCT05894954
    Conditions
    Mild Cognitive Impairment; Dementia, Mild
    Interventions
    Precision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-07-31
    Completion
    2026-02-09
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Dementia, Mild
    InterventionPrecision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    PhasePhase 3
    Registry statusCompleted
  • Famciclovir in Multiple Sclerosis

    NCT05283551 · start 2020-11-25

    Registered record
    Registry ID
    NCT05283551
    Conditions
    Multiple Sclerosis
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-25
    Completion
    2023-11-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionFamciclovir
    PhasePhase 2
    Registry statusUnknown
  • Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia

    NCT03120962 · start 2017-05

    Registered record
    Registry ID
    NCT03120962
    Conditions
    Herpes Zoster; Post-herpetic Neuralgia
    Interventions
    Oxycodone; Gabapentin; Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-05
    Completion
    2020-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster; Post-herpetic Neuralgia
    InterventionOxycodone; Gabapentin; Famciclovir
    PhaseNot applicable
    Registry statusUnknown
  • Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes

    NCT01281007 · start 2012-07

    Registered record
    Registry ID
    NCT01281007
    Conditions
    GENITAL HERPES
    Interventions
    Famciclovir; Aciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGENITAL HERPES
    InterventionFamciclovir; Aciclovir
    PhasePhase 3
    Registry statusCompleted
  • Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster

    NCT01327144 · start 2012-06

    Registered record
    Registry ID
    NCT01327144
    Conditions
    Herpes Zoster
    Interventions
    Famciclovir; Aciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2017-07
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster
    InterventionFamciclovir; Aciclovir
    PhasePhase 3
    Registry statusCompleted
  • Famvir for Treatment of Hearing in Unilateral Meniere's Disease

    NCT01526408 · start 2011-12

    Registered record
    Registry ID
    NCT01526408
    Conditions
    Meniere's Disease
    Interventions
    Famciclovir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2015-03
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeniere's Disease
    InterventionFamciclovir; Placebo
    PhasePhase 3
    Registry statusTerminated
  • Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

    NCT00878072 · start 2009-03-25

    Registered record
    Registry ID
    NCT00878072
    Conditions
    Herpes Labialis
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2009-03-25
    Completion
    2010-06-02
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Labialis
    InterventionFamciclovir
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

    NCT01154543 · start 2008-03

    Registered record
    Registry ID
    NCT01154543
    Conditions
    HIV Positive; Herpes Simplex, Genital
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Positive; Herpes Simplex, Genital
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted
  • Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

    NCT00448227 · start 2007-10

    Registered record
    Registry ID
    NCT00448227
    Conditions
    Herpes Simplex
    Interventions
    famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    Not recorded
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Simplex
    Interventionfamciclovir
    PhasePhase 2
    Registry statusCompleted
  • Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

    NCT01321502 · start 2007-07

    Registered record
    Registry ID
    NCT01321502
    Conditions
    Herpes
    Interventions
    famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-07
    Completion
    2007-07
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes
    Interventionfamciclovir
    PhaseNot applicable
    Registry statusCompleted
  • Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions

    NCT01321515 · start 2007-07

    Registered record
    Registry ID
    NCT01321515
    Conditions
    Herpes
    Interventions
    famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-07
    Completion
    2007-07
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes
    Interventionfamciclovir
    PhaseNot applicable
    Registry statusCompleted